Key points are not available for this paper at this time.
You have accessJournal of UrologyStone Disease: Medical three others experienced mild, self-resolving effects and yet stayed on the medication. CONCLUSIONS: Cystinuric patients treated with a SGLT2 inhibitor experienced fewer stone events while on medication compared to their historic rates and also exhibited decreased or stable stone growth. There were few medication related side effects, almost all of which were temporary. SGLT2 inhibitors may be a promising long-term therapy for patients with cystinuria. Download PPT Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e421 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Wilson Sui More articles by this author Heiko Yang More articles by this author Manoj Desai More articles by this author Thomas Chi More articles by this author Marshall Stoller More articles by this author Expand All Advertisement PDF downloadLoading ...
Sui et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: